RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,665,076 | +2.4% | 217,657 | 0.0% | 0.37% | +1.9% |
| Q2 2023 | $1,625,898 | +12.0% | 217,657 | 0.0% | 0.36% | -1.9% |
| Q1 2023 | $1,451,772 | -13.5% | 217,657 | 0.0% | 0.37% | -17.9% |
| Q4 2022 | $1,678,135 | -27.5% | 217,657 | 0.0% | 0.45% | -27.5% |
| Q3 2022 | $2,316,000 | +30.7% | 217,657 | 0.0% | 0.62% | +38.9% |
| Q2 2022 | $1,772,000 | +13.7% | 217,657 | 0.0% | 0.44% | +61.8% |
| Q1 2022 | $1,559,000 | -58.2% | 217,657 | 0.0% | 0.28% | -46.9% |
| Q4 2021 | $3,729,000 | +138.0% | 217,657 | +219.6% | 0.52% | +113.2% |
| Q3 2021 | $1,567,000 | -37.0% | 68,104 | 0.0% | 0.24% | -43.1% |
| Q2 2021 | $2,486,000 | – | 68,104 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |